Modulating Inflammation for the Treatment of Disease: Novel Therapeutic Approaches and Modalities

Agenda

8:00-8:30  Registration and coffee
8:30-8:45  Welcome and opening remarks

Morning Session  
*Moderated by Dirk Smith, Cascadia Drug Development Group*

8:45-9:15  Mike Wittekind, CEO, Olympic Protein Technologies  
*New developments for extending functionalities of protein therapeutics*

9:15-9:45  Gabriela Hernandez-Hoyos, Senior Director of Immunobiology, Aptevo Therapeutics  
*APVO210: Improving the biological properties of IL-10 for autoimmune and inflammatory diseases through a targeted cytokine bispecific ADAPTIR molecule*

9:45-10:15  Fred Ramsdell, Vice President, Research Parker Institute for Cancer Immunotherapy  
*Neoantigens and immunogenicity in cancer patients*

10:15-10:45  coffee break and poster viewing

10:45-11:15  John Babcook, Senior VP, Discovery Research, Zymeworks Inc.  
*Azymetric™ Antibody Platform: Enabling Bispecific Therapeutics*

11:15-11:45  Santanu Bose, Professor, Washington State University, Dept of Veterinary Microbiology and Pathology, College of Veterinary Medicine  
*Therapeutic activity of S100A9 blocking antibody for treatment of influenza A virus associated pneumonia*

11:45-1:00  Lunch and poster viewing (lunch will be provided)

Afternoon Session Chris  
*Moderated by Chris Mehlin, Fred Hutchinson Cancer Research Center*

1:00-1:30  Chris Mehlin, Director, Peptide Drug Discovery Initiative, FHCRC  
*Simultaneous Multiple Interaction T cell Engaging (SMITE) Bispecifics: Putting some teeth into BiTEs*

1:30-2:00  Lili Cheng, Research Fellow, Protagonist Therapeutics  
*Discovery and preclinical development of PTG-200, an oral peptide antagonist of the IL-23 receptor*

2:00-2:30  Steve Ziegler, Director of Immunology, Benaroya Research Institute
2:30-2:45  Short break

2:45-3:15  Wei Yan, Founder and CEO, Sound Biologics  
*Development of MabPair Technology, a Novel Platform for Antibody Combination Therapy*

3:15-3:35  short talk: Mark Bazett, Director, Preclinical and Translational Research, Qu Biologics  
*Site-specific anti-cancer efficacy with bacterial-derived Immunotherapies*

3:40-4:00  Closing remarks

4:00-5:00  Post meeting reception